Safety and Efficacy of DNK333 in Atopic Dermatitis Patients

NCT01033097 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Pruritus in Patients With Atopic Dermatitis

Interventions

DRUG: DNK333 5 mg
DRUG: Placebo to 5 mg
DRUG: DNK333 25 mg
DRUG: Placebo to 25 mg
DRUG: DNK333 100 mg
DRUG: Placebo to 100 mg
DRUG: Betamethasone 4 mg
DRUG: DNK333 1mg
DRUG: Placebo to 1mg

Sponsor

Novartis Pharmaceuticals